Cargando…
Management of psychotropic medications in adults with intellectual disability: a scoping review protocol
Introduction: Psychotropic medications are commonly prescribed among adults with intellectual disability (ID), often in the absence of a psychiatric diagnosis. As such, there is great disparity between the estimated prevalence of mental illness and the rates of psychotropic medication use amongst pe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503790/ https://www.ncbi.nlm.nih.gov/pubmed/34693205 http://dx.doi.org/10.12688/hrbopenres.13170.2 |
_version_ | 1784581202465783808 |
---|---|
author | Costello, Ashley Hehir, Cian Sharma, Drona Hudson, Eithne Doody, Owen Kelly, Dervla |
author_facet | Costello, Ashley Hehir, Cian Sharma, Drona Hudson, Eithne Doody, Owen Kelly, Dervla |
author_sort | Costello, Ashley |
collection | PubMed |
description | Introduction: Psychotropic medications are commonly prescribed among adults with intellectual disability (ID), often in the absence of a psychiatric diagnosis. As such, there is great disparity between the estimated prevalence of mental illness and the rates of psychotropic medication use amongst people with ID. ‘Off-label’ use of these medications may account for much of this discrepancy, in particular their use in the management of challenging behaviour. This has come under scrutiny due to the myriad of side effects and the deficiency of high-quality data supporting their use for this indication. Understanding the causes and justifications for such disparity is essential in discerning the efficacy of current prescription practice. Objective: To explore the existing evidence base regarding the prescription and management of psychotropic medications in adults with ID. The aim will be achieved through identifying the psychotropic medications commonly prescribed, the underlying rationale(s) for their prescription and the evidence available that demonstrates their appropriateness and effectiveness. Additionally, the paper will seek to evaluate the availability of any existing guidance that informs the management of these medications, and the evidence and outcomes of psychotropic medication dose reduction and/or cessation interventions. Inclusion criteria: This review will consider studies that focus on the use of psychotropic medications amongst patients with ID. Methods: Research studies (qualitative, quantitative and mixed design) and Grey Literature (English) will be included. The search will be conducted without time restrictions. Databases will include: Ovid MEDLINE, Embase, CINAHL, JBI Evidence Synthesis, Cochrane Central Register of Controlled Trials, Cochrane Databased of Systematic Reviews, PsycINFO and Scopus. A three-step search strategy will be followed, with results screened by two independent reviewers. Data will be extracted independently by two reviewers using a data extraction tool with results mapped and presented using a narrative form supported by tables and diagrams. |
format | Online Article Text |
id | pubmed-8503790 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | F1000 Research Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-85037902021-10-22 Management of psychotropic medications in adults with intellectual disability: a scoping review protocol Costello, Ashley Hehir, Cian Sharma, Drona Hudson, Eithne Doody, Owen Kelly, Dervla HRB Open Res Study Protocol Introduction: Psychotropic medications are commonly prescribed among adults with intellectual disability (ID), often in the absence of a psychiatric diagnosis. As such, there is great disparity between the estimated prevalence of mental illness and the rates of psychotropic medication use amongst people with ID. ‘Off-label’ use of these medications may account for much of this discrepancy, in particular their use in the management of challenging behaviour. This has come under scrutiny due to the myriad of side effects and the deficiency of high-quality data supporting their use for this indication. Understanding the causes and justifications for such disparity is essential in discerning the efficacy of current prescription practice. Objective: To explore the existing evidence base regarding the prescription and management of psychotropic medications in adults with ID. The aim will be achieved through identifying the psychotropic medications commonly prescribed, the underlying rationale(s) for their prescription and the evidence available that demonstrates their appropriateness and effectiveness. Additionally, the paper will seek to evaluate the availability of any existing guidance that informs the management of these medications, and the evidence and outcomes of psychotropic medication dose reduction and/or cessation interventions. Inclusion criteria: This review will consider studies that focus on the use of psychotropic medications amongst patients with ID. Methods: Research studies (qualitative, quantitative and mixed design) and Grey Literature (English) will be included. The search will be conducted without time restrictions. Databases will include: Ovid MEDLINE, Embase, CINAHL, JBI Evidence Synthesis, Cochrane Central Register of Controlled Trials, Cochrane Databased of Systematic Reviews, PsycINFO and Scopus. A three-step search strategy will be followed, with results screened by two independent reviewers. Data will be extracted independently by two reviewers using a data extraction tool with results mapped and presented using a narrative form supported by tables and diagrams. F1000 Research Limited 2022-01-12 /pmc/articles/PMC8503790/ /pubmed/34693205 http://dx.doi.org/10.12688/hrbopenres.13170.2 Text en Copyright: © 2022 Costello A et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Study Protocol Costello, Ashley Hehir, Cian Sharma, Drona Hudson, Eithne Doody, Owen Kelly, Dervla Management of psychotropic medications in adults with intellectual disability: a scoping review protocol |
title | Management of psychotropic medications in adults with intellectual disability: a scoping review protocol |
title_full | Management of psychotropic medications in adults with intellectual disability: a scoping review protocol |
title_fullStr | Management of psychotropic medications in adults with intellectual disability: a scoping review protocol |
title_full_unstemmed | Management of psychotropic medications in adults with intellectual disability: a scoping review protocol |
title_short | Management of psychotropic medications in adults with intellectual disability: a scoping review protocol |
title_sort | management of psychotropic medications in adults with intellectual disability: a scoping review protocol |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503790/ https://www.ncbi.nlm.nih.gov/pubmed/34693205 http://dx.doi.org/10.12688/hrbopenres.13170.2 |
work_keys_str_mv | AT costelloashley managementofpsychotropicmedicationsinadultswithintellectualdisabilityascopingreviewprotocol AT hehircian managementofpsychotropicmedicationsinadultswithintellectualdisabilityascopingreviewprotocol AT sharmadrona managementofpsychotropicmedicationsinadultswithintellectualdisabilityascopingreviewprotocol AT hudsoneithne managementofpsychotropicmedicationsinadultswithintellectualdisabilityascopingreviewprotocol AT doodyowen managementofpsychotropicmedicationsinadultswithintellectualdisabilityascopingreviewprotocol AT kellydervla managementofpsychotropicmedicationsinadultswithintellectualdisabilityascopingreviewprotocol |